Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsOther Non-Current AssetsPayablesProperty, Plant & Equipment (Net)Retained EarningsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pharming (PHAR) Cash & Equivalents (2019 - 2024)

Historic Cash & Equivalents for Pharming (PHAR) over the last 7 years, with Q3 2025 value amounting to $132.4 million.

  • Pharming's Cash & Equivalents changed N/A to $132.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $132.4 million, marking a year-over-year change of. This contributed to the annual value of $54.9 million for FY2024, which is 1100.89% down from last year.
  • Per Pharming's latest filing, its Cash & Equivalents stood at $132.4 million for Q3 2025.
  • In the past 5 years, Pharming's Cash & Equivalents registered a high of $212.2 billion during Q1 2021, and its lowest value of $193714.3 during Q4 2021.
  • Its 5-year average for Cash & Equivalents is $23.7 billion, with a median of $183.3 million in 2021.
  • Within the past 5 years, the most significant YoY rise in Pharming's Cash & Equivalents was 10693492.1% (2022), while the steepest drop was 9991.06% (2022).
  • Quarter analysis of 5 years shows Pharming's Cash & Equivalents stood at $193714.3 in 2021, then skyrocketed by 106934.92% to $207.3 million in 2022, then tumbled by 70.22% to $61.7 million in 2023, then decreased by 11.01% to $54.9 million in 2024, then surged by 140.92% to $132.4 million in 2025.
  • Its Cash & Equivalents was $132.4 million in Q3 2025, compared to $92.1 million in Q2 2025 and $60.1 million in Q1 2025.